Trial Profile
A retrospective study to investigate safety and the efficacy of Nivolumab in patients with relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2017 New trial record
- 07 Mar 2017 Results published in the Blood